Adam M. Spivak
( out of 58 reviews )

Adam M. Spivak, MD, FACP

Languages spoken: English

Clinical Locations

University of Utah Hospital

Infectious Diseases, Area E
Salt Lake City
801-585-2031
Directions

  • Dr. Spivak joined the faculty of the University of Utah Department of Internal Medicine (Division of Infectious Diseases) in the fall of 2011 after completing residency and fellowship training at Johns Hopkins Hospital in Baltimore, Maryland. He cares for people living with HIV infection and serves as the medical director of the HIV Clinic, and attends on the inpatient Infectious Diseases consult service at the University of Utah Hospital. Dr. Spivak teaches in the medical school, mentors post-graduate trainees, conducts translational research on HIV persistence and eradication, and is a co-founder and leader of Utah's first and only free HIV prevention clinic. He is a scientific member of the NIH AIDS Clinical Trial Group (ACTG) and is leading two interventional clinical trials studying HIV persistence and aging in the ACTG network.

    Specialties

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Infectious Disease)

    Patient Rating

    4.8 /5
    ( out of 58 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    June 06, 2025
    UNIVERSITY HOSPITAL

    Excellent care! Great bedside manner. He is a good communicator and very kind and excellent in his specialties.

    April 18, 2025
    UNIVERSITY HOSPITAL

    Haven't yet had a one on one appointment with him

    March 29, 2025
    UNIVERSITY HOSPITAL

    have not seen him yet but my intake was very good

    March 13, 2025
    UNIVERSITY HOSPITAL

    He is very kind [TRANSLATED]

    February 14, 2025
    UNIVERSITY HOSPITAL

    He's great.

    February 09, 2025
    UNIVERSITY HOSPITAL

    Adam is a great doctor and a very nice person

    February 06, 2025
    UNIVERSITY HOSPITAL

    Caring doctor who works hard treat patients with kindness and dignity.

    January 09, 2025
    UNIVERSITY HOSPITAL

    Dr. Spivak is warm and engaging. He is also very flexible to my needs.

    January 02, 2025
    UNIVERSITY HOSPITAL

    Most intelligent doctor I've ever met outstanding personality extremely nice I have been under his care for 12 years. He's the best!!

  • Dr. Spivak joined the faculty of the University of Utah Department of Internal Medicine (Division of Infectious Diseases) in the fall of 2011 after completing residency and fellowship training at Johns Hopkins Hospital in Baltimore, Maryland. He cares for people living with HIV infection and serves as the medical director of the HIV Clinic, and attends on the inpatient Infectious Diseases consult service at the University of Utah Hospital. Dr. Spivak teaches in the medical school, mentors post-graduate trainees, conducts translational research on HIV persistence and eradication, and is a co-founder and leader of Utah's first and only free HIV prevention clinic. He is a scientific member of the NIH AIDS Clinical Trial Group (ACTG) and is leading two interventional clinical trials studying HIV persistence and aging in the ACTG network.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Associate Professor
    Pathology -Adjunct Assistant Professor
    Academic Divisions Infectious Diseases
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Infectious Disease)

    Education history

    Fellowship Infectious Diseases - Johns Hopkins University School of Medicine Fellow
    Chief Resident Internal Medicine - Johns Hopkins University School of Medicine Chief Resident
    Residency Internal Medicine - Johns Hopkins University School of Medicine Resident
    Internship Internal Medicine - Johns Hopkins University School of Medicine Intern
    Professional Medical Medicine - University of Maryland School of Medicine M.D.
    Undergraduate English Literature - Princeton University A.B.

    Selected Publications

    Journal Article

    1. Rodrguez-Mora S, Snchez-Menndez C, Bautista-Carrascosa G, Mateos E, Moreno-Serna L, Megas D, Cantn J, Garca-Gutirrez V, Murciano-Antn MA, Cervero M, Spivak A, Planelles V, Coiras M (2024). Dasatinib interferes with HIV-1 proviral integration and the inflammatory potential of monocyte-derived macrophages from people with HIV. Biochem Pharmacol, 229, 116512. (Read full article)
    2. Gillis N, Dickey BL, Colin-Leitzinger C, Tang YH, Putney RM, Mesa TE, Yoder SJ, Suneja G, Spivak AM, Patel AB, Extermann M, Giuliano AR, Teng M, Kresovich J, Berglund A, Coghill AE (2024). Clonal Hematopoiesis in Patients With Human Immunodeficiency Virus and Cancer. J Infect Dis, 230(3), 680-688. (Read full article)
    3. Manzanares M, Ramos-Martn F, Rodrguez-Mora S, Casado-Fernndez G, Snchez-Menndez C, Simn-Rueda A, Mateos E, Cervero M, Spivak AM, Planelles V, Torres M, Garca-Gutirrez V, Coiras M (2024). Sustained antiviral response against in vitro HIV-1 infection in peripheral blood mononuclear cells from people with chronic myeloid leukemia treated with ponatinib. Front Pharmacol, 15, 1426974. (Read full article)
    4. Ho TF, Zenger B, Mark B, Hiatt L, Sullivan E, Steinberg BA, Lyons A, Spivak AM, Agarwal C, Adelman M, Hotaling J, Kiraly B, Talboys S (2024). Characteristics of a transgender and gender-diverse patient population in Utah: Use of electronic health records to advance clinical and health equity research. PLoS One, 19(5), e0302895. (Read full article)
    5. Ravkov EV, Williams ESCP, Elgort M, Barker AP, Planelles V, Spivak AM, Delgado JC, Lin L, Hanley TM (2024). Reduced monocyte proportions and responsiveness in convalescent COVID-19 patients. Front Immunol, 14, 1329026. (Read full article)
    6. Dickey BL, Putney RM, Suneja G, Kresovich JK, Spivak AM, Patel AB, Teng M, Extermann M, Giuliano AR, Gillis N, Berglund A, Coghill AE (2023). Differences in epigenetic age by HIV status among patients with a non-AIDS defining cancer. AIDS, 37(13), 2049-2057. (Read full article)
    7. Reiersen AM, Mattar C, Bender Ignacio RA, Boulware DR, Lee TC, Hess R, Lankowski AJ, McDonald EG, Miller JP, Powderly WG, Pullen MF, Rado JT, Rich MW, Schiffer JT, Schweiger J, Spivak AM, Stevens A, Vigod SN, Agarwal P, Yang L, Yingling M, Gettinger TR, Zorumski CF, Lenze EJ (2023). The STOP COVID 2 Study: Fluvoxamine vs Placebo for Outpatients With Symptomatic COVID-19, a Fully Remote Randomized Controlled Trial. Open Forum Infect Dis, 10(8), ofad419. (Read full article)
    8. Spivak AM, Barney BJ, Greene T, Holubkov R, Olsen CS, Bridges J, Srivastava R, Webb B, Sebahar F, Huffman A, Pacchia CF, Dean JM, Hess R (2023). A Randomized Clinical Trial Testing Hydroxychloroquine for Reduction of SARS-CoV-2 Viral Shedding and Hospitalization in Early Outpatient COVID-19 Infection. Microbiol Spectr, 11(2), e0467422. (Read full article)
    9. Mitj O, Reis G, Boulware DR, Spivak AM, Sarwar A, Johnston C, Webb B, Hill MD, Smith D, Kremsner P, Curran M, Carter D, Alexander J, Corbacho M, Lee TC, Hullsiek KH, McDonald EG, Hess R, Hughes M, Baeten JM, Schwartz I, Metz L, Richer L, Chew KW, Daar E, Wohl D, Dunne M (2023). Hydroxychloroquine for treatment of non-hospitalized adults with COVID-19: A meta-analysis of individual participant data of randomized trials. Clin Transl Sci, 16(3), 524-535. (Read full article)
    10. Cruz-Lorenzo E, Ramirez NP, Lee J, Pandhe S, Wang L, Hernandez-Doria J, Spivak AM, Planelles V, Petersen T, Jain MK, Martinez ED, DOrso I (2022). Host Cell Redox Alterations Promote Latent HIV-1 Reactivation through Atypical Transcription Factor Cooperativity. Viruses, 14(10). (Read full article)
    11. Larragoite ET, Nell RA, Martins LJ, Barrows LR, Planelles V, Spivak AM (2021). Histone deacetylase inhibition reduces deleterious cytokine release induced by ingenol stimulation. Biochem Pharmacol, 195, 114844. (Read full article)
    12. Williams ESCP, Szaniawski MA, Martins LJ, Innis EA, Alcam J, Hanley TM, Spivak AM, Coiras M, Planelles V (2022). Dasatinib: effects on the macrophage phospho proteome with a focus on SAMHD1 and HIV-1 infection. Clin Res HIV AIDS, 8(1). (Read full article)
    13. Williams ES, Martins TB, Shah KS, Hill HR, Coiras M, Spivak AM, Planelles V (2022). Cytokine Deficiencies in Patients with Long-COVID. J Clin Cell Immunol, 13(6). (Read full article)
    14. Redecke V, Tawaratsumida K, Larragoite ET, Williams ESCP, Planelles V, Spivak AM, Hirayama L, Elgort M, Swenson S, Smith R, Worthen B, Zimmerman R, Slev P, Cahoon B, Astill M, Hcker H (2021). A rapid and affordable point of care test for antibodies against SARS-CoV-2 based on hemagglutination and artificial intelligence interpretation. Sci Rep, 11(1), 24507. (Read full article)
    15. Innis EA, Levinger C, Szaniawski MA, Williams ESCP, Alcam J, Bosque A, Schiffer JT, Coiras M, Spivak AM, Planelles V (2021). Pharmacologic control of homeostatic and antigen-driven proliferation to target HIV-1 persistence. Biochem Pharmacol, 194, 114816. (Read full article)
    16. Tsai YC, Nell RA, Buckendorf JE, Ksz N, Mwangi PW, Berkecz R, Rdei D, Vasas A, Spivak AM, Hohmann J (2021). Bioactive Compounds from Euphorbia usambarica Pax. with HIV-1 Latency Reversal Activity. Pharmaceuticals (Basel), 14(7). (Read full article)
    17. Sarabia I, Novis CL, Macedo AB, Takata H, Nell R, Kakazu JC, Furler RL, Shakya B, Schubert HL, Hill CP, DePaula-Silva AB, Spivak AM, Trautmann L, Planelles V, Bosque A (2021). Activation of the Anti-Oxidative Stress Response Reactivates Latent HIV-1 Through the Mitochondrial Antiviral Signaling Protein Isoform MiniMAVS. Front Immunol, 12, 682182. (Read full article)
    18. Trivedi S, Afroz T, Bennett MS, Angell K, Barros F, Nell RA, Ying J, Spivak AM, Leung DT (2021). Diverse Mucosal-Associated Invariant TCR Usage in HIV Infection. Immunohorizons, 5(5), 360-369. (Read full article)
    19. Gibson EG, Pender M, Angerbauer M, Cook C, Jones B, Spivak AM, Spivak ES, Swaminathan S (2021). Prolonged SARS-CoV-2 Illness in a Patient Receiving Ocrelizumab for Multiple Sclerosis. Open Forum Infect Dis, 8(7), ofab176. (Read full article)
    20. Zheng Y, Larragoite ET, Williams ESCP, Lama J, Cisneros I, Delgado JC, Slev P, Rychert J, Innis EA, Coiras M, Rondina MT, Spivak AM, Planelles V (2021). Neutralization assay with SARS-CoV-1 and SARS-CoV-2 spike pseudotyped murine leukemia virions. Virol J, 18(1), 1. (Read full article)
    21. Schynkel T, Szaniawski MA, Spivak AM, Bosque A, Planelles V, Vandekerckhove L, Trypsteen W (2020). Interferon-Mediated Long Non-Coding RNA Response in Macrophages in the Context of HIV. Int J Mol Sci, 21(20). (Read full article)
    22. Luetkens T, Metcalf R, Planelles V, Zheng Y, Larragoite ET, Spivak ES, Spivak AM, Steinbach M, Blaylock RC, Avila SV, Hankey KG, Martins TB, Slev PR, Mannuel HD, Sajadi M, Rapoport AP, Atanackovic D (2020). Successful transfer of anti-SARS-CoV-2 immunity using convalescent plasma in an MM patient with hypogammaglobulinemia and COVID-19. Blood Adv, 4(19), 4864-4868. (Read full article)
    23. Abdel-Mohsen M, Richman D, Siliciano RF, Nussenzweig MC, Howell BJ, Martinez-Picado J, Chomont N, Bar KJ, Yu XG, Lichterfeld M, Alcami J, Hazuda D, Bushman F, Siliciano JD, Betts MR, Spivak AM, Planelles V, Hahn BH, Smith DM, Ho YC, Buzon MJ, Gaebler C, Paiardini M, Li Q, Estes JD, Hope TJ, Kostman J, Mounzer K, Caskey M, Fox L, Frank I, Riley JL, Tebas P, Montaner LJ, BEAT-HIV Delaney Collaboratory to Cure HIV-1 infection (2020). Recommendations for measuring HIV reservoir size in cure-directed clinical trials. Nat Med, 26(9), 1339-1350. (Read full article)
    24. Sorensen ES, Macedo AB, Resop RS, Howard JN, Nell R, Sarabia I, Newman D, Ren Y, Jones RB, Planelles V, Spivak AM, Bosque A (2020). Structure-Activity Relationship Analysis of Benzotriazine Analogues as HIV-1 Latency-Reversing Agents. Antimicrob Agents Chemother, 64(8). (Read full article)
    25. Pache L, Marsden MD, Teriete P, Portillo AJ, Heimann D, Kim JT, Soliman MSA, Dimapasoc M, Carmona C, Celeridad M, Spivak AM, Planelles V, Cosford NDP, Zack JA, Chanda SK (2020). Pharmacological Activation of Non-canonical NF-κB Signaling Activates Latent HIV-1 Reservoirs In Vivo. Cell Rep Med, 1(3), 100037. (Read full article)
    26. Pan F, Xiao X, Guo J, Song Y, Li H, Patel DP, Spivak AM, Alukal JP, Zhang X, Xiong C, Li PS, Hotaling JM (2020). No evidence of severe acute respiratory syndrome-coronavirus 2 in semen of males recovering from coronavirus disease 2019. Fertil Steril, 113(6), 1135-1139. (Read full article)
    27. Rodrguez-Mora S, Spivak AM, Szaniawski MA, Lpez-Huertas MR, Alcam J, Planelles V, Coiras M (2019). Tyrosine Kinase Inhibition: a New Perspective in the Fight against HIV. Curr HIV/AIDS Rep, 16(5), 414-422. (Read full article)
    28. Szaniawski MA, Spivak AM, Bosque A, Planelles V (2018). Sex Influences SAMHD1 Activity and Susceptibility to Human Immunodeficiency Virus-1 in Primary Human Macrophages. J Infect Dis, 219(5), 777-785. (Read full article)
    29. Reeves DB, Duke ER, Wagner TA, Palmer SE, Spivak AM, Schiffer JT (2018). A majority of HIV persistence during antiretroviral therapy is due to infected cell proliferation. Nat Commun, 9(1), 4811. (Read full article)
    30. Spivak AM, Nell RA, Petersen M, Martins L, Sebahar P, Looper RE, Planelles V (2018). Synthetic Ingenols Maximize Protein Kinase C-Induced HIV-1 Latency Reversal. Antimicrob Agents Chemother, 62(11). (Read full article)
    31. Macedo AB, Novis CL, De Assis CM, Sorensen ES, Moszczynski P, Huang SH, Ren Y, Spivak AM, Jones RB, Planelles V, Bosque A (2018). Dual TLR2 and TLR7 agonists as HIV latency-reversing agents. JCI Insight, 3(19). (Read full article)
    32. Macedo AB, Resop RS, Martins LJ, Szaniawski MA, Sorensen ES, Spivak AM, Nixon DF, Jones RB, Planelles V, Bosque A (2018). Influence of Biological Sex, Age, and HIV Status in an In Vitro Primary Cell Model of HIV Latency Using a CXCR4 Tropic Virus. AIDS Res Hum Retroviruses, 34(9), 769-777. (Read full article)
    33. Szaniawski MA, Spivak AM, Cox JE, Catrow JL, Hanley T, Williams ESCP, Tremblay MJ, Bosque A, Planelles V (2018). SAMHD1 Phosphorylation Coordinates the Anti-HIV-1 Response by Diverse Interferons and Tyrosine Kinase Inhibition. mBio, 9(3). (Read full article)
    34. Abdel-Mohsen M, Kuri-Cervantes L, Grau-Exposito J, Spivak AM, Nell RA, Tomescu C, Vadrevu SK, Giron LB, Serra-Peinado C, Genesc M, Castellv J, Wu G, Del Rio Estrada PM, Gonzlez-Navarro M, Lynn K, King CT, Vemula S, Cox K, Wan Y, Li Q, Mounzer K, Kostman J, Frank I, Paiardini M, Hazuda D, Reyes-Tern G, Richman D, Howell B, Tebas P, Martinez-Picado J, Planelles V, Buzon MJ, Betts MR, Montaner LJ (2018). CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells. Sci Transl Med, 10(437). (Read full article)
    35. Bosque A, Nilson KA, Macedo AB, Spivak AM, Archin NM, Van Wagoner RM, Martins LJ, Novis CL, Szaniawski MA, Ireland CM, Margolis DM, Price DH, Planelles V (2017). Benzotriazoles Reactivate Latent HIV-1 through Inactivation of STAT5 SUMOylation. Cell Rep, 18(5), 1324-1334. (Read full article)
    36. Spivak AM, Larragoite ET, Coletti ML, Macedo AB, Martins LJ, Bosque A, Planelles V (2016). Janus kinase inhibition suppresses PKC-induced cytokine release without affecting HIV-1 latency reversal ex vivo. Retrovirology, 13(1), 88. (Read full article)
    37. Garrido C, Spivak AM, Soriano-Sarabia N, Checkley MA, Barker E, Karn J, Planelles V, Margolis DM (2016). HIV Latency-Reversing Agents Have Diverse Effects on Natural Killer Cell Function. Front Immunol, 7, 356. (Read full article)
    38. Martins LJ, Bonczkowski P, Spivak AM, De Spiegelaere W, Novis CL, DePaula-Silva AB, Malatinkova E, Trypsteen W, Bosque A, Vanderkerckhove L, Planelles V (2016). Modeling HIV-1 Latency in Primary T Cells Using a Replication-Competent Virus. AIDS Res Hum Retroviruses, 32(2), 187-93. (Read full article)
    39. Spivak AM, Bosque A, Balch AH, Smyth D, Martins L, Planelles V (2015). Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients. Antimicrob Agents Chemother, 59(10), 5984-91. (Read full article)
    40. Pache L, Dutra MS, Spivak AM, Marlett JM, Murry JP, Hwang Y, Maestre AM, Manganaro L, Vamos M, Teriete P, Martins LJ, Knig R, Simon V, Bosque A, Fernandez-Sesma A, Cosford ND, Bushman FD, Young JA, Planelles V, Chanda SK (2015). BIRC2/cIAP1 Is a Negative Regulator of HIV-1 Transcription and Can Be Targeted by Smac Mimetics to Promote Reversal of Viral Latency. Cell Host Microbe, 18(3), 345-53. (Read full article)
    41. Spivak AM, Andrade A, Eisele E, Hoh R, Bacchetti P, Bumpus NN, Emad F, Buckheit R 3rd, McCance-Katz EF, Lai J, Kennedy M, Chander G, Siliciano RF, Siliciano JD, Deeks SG (2014). A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin Infect Dis, 58(6), 883-90. (Read full article)
    42. Weil AF, Ghosh D, Zhou Y, Seiple L, McMahon MA, Spivak AM, Siliciano RF, Stivers JT (2013). Uracil DNA glycosylase initiates degradation of HIV-1 cDNA containing misincorporated dUTP and prevents viral integration. Proc Natl Acad Sci U S A, 110(6), E448-57. (Read full article)
    43. Spivak AM, Salgado M, Rabi SA, OConnell KA, Blankson JN (2011). Circulating monocytes are not a major reservoir of HIV-1 in elite suppressors. J Virol, 85(19), 10399-403. (Read full article)
    44. Gaillard S, Dinoso JB, Marsh JA, DeZern AE, OConnell KA, Spivak AM, Alwood K, Durand CM, Ambinder RF, Blankson JN (2011). Sustained elite suppression of replication competent HIV-1 in a patient treated with rituximab based chemotherapy. J Clin Virol, 51(3), 195-8. (Read full article)
    45. Spivak AM, Rabi SA, McMahon MA, Shan L, Sedaghat AR, Wilke CO, Siliciano RF (2011). Short communication: dynamic constraints on the second phase compartment of HIV-infected cells. AIDS Res Hum Retroviruses, 27(7), 759-61. (Read full article)
    46. Pradilla G, Nagahama Y, Spivak AM, Bydon A, Rigamonti D (2010). Spinal epidural abscess: current diagnosis and management. Curr Infect Dis Rep, 12(6), 484-91. (Read full article)
    47. Dinoso JB, Kim SY, Wiegand AM, Palmer SE, Gange SJ, Cranmer L, OShea A, Callender M, Spivak A, Brennan T, Kearney MF, Proschan MA, Mican JM, Rehm CA, Coffin JM, Mellors JW, Siliciano RF, Maldarelli F (2009). Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A, 106(23), 9403-8. (Read full article)

    Review

    1. Szaniawski MA, Spivak AM (2020). Senotherapeutics and HIV-1 Persistence. [Review]. Curr HIV/AIDS Rep, 17(3), 219-225. (Read full article)
    2. Szaniawski MA, Spivak AM (2019). Senotherapeutics for HIV and aging. [Review]. Curr Opin HIV AIDS, 15(2), 83-93. (Read full article)
    3. Spivak AM, Planelles V (2018). Novel Latency Reversal Agents for HIV-1 Cure. [Review]. Annu Rev Med, 69, 421-436. (Read full article)
    4. Spivak AM, Planelles V (2016). HIV-1 Eradication: Early Trials (and Tribulations). [Review]. Trends Mol Med, 22(1), 10-27. (Read full article)
    5. Barber AE, Norton JP, Spivak AM, Mulvey MA (2013). Urinary tract infections: current and emerging management strategies. [Review]. Clin Infect Dis, 57(5), 719-24. (Read full article)
    6. Spivak AM, Sydnor ER, Blankson JN, Gallant JE (2010). Seronegative HIV-1 infection: a review of the literature. [Review]. AIDS, 24(10), 1407-14. (Read full article)

    Book

    1. Spivak AM (2008). Harrison’s Principles of Internal Medicine Self-Assessment & Board Review. [contributing editor] (17th). New York, NY: McGraw Hill.

    Book Chapter

    1. Spivak A, Zaas A, Cheng A, Auwaerter P (2006). CNS Infections. In The Osler Medical Handbook (2nd, Chapter 57). Philadelphia, PA: Elsevier Mosby.
    2. Spivak A, Sosnay P, Cosgrove S (2006). Soft Tissue and Bone Infection. In The Osler Medical Handbook (2nd, Chapter 65). Philadelphia, PA: Elsevier Mosby.

    Commentary

    1. Larragoite ET, Spivak AM (2019). Down but not out. Elife, 8. (Read full article)

    Case Report

    1. Szaniawski MA, Spivak AM (2019). Recurrent Paenibacillus infection. Oxf Med Case Reports, 2019(5), omz034. (Read full article)
    2. Johnson RA, Spivak AM (2017). Lues Maligna. Open Forum Infect Dis, 4(3), ofx139. (Read full article)
    3. Rachakonda T, Kendall B, Spivak AM, Boltax J (2017). Pleural Effusion Caused by Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer. Open Forum Infect Dis, 4(3), ofx126. (Read full article)
    4. Spivak AM, Brennan TP, OConnell KA, Sydnor E, Williams TM, Siliciano RF, Gallant JE, Blankson JN (2010). A case of seronegative HIV-1 infection. J Infect Dis, 201(3), 341-5. (Read full article)
    5. Vargas JD, Spivak AM (2009). A perfect storm. Gastric bezoar. Am J Med, 122(6), 519-21. (Read full article)
    6. Rodriguez ED, Bluebond-Langner R, Spivak AM, Eisig SB (2007). Surgical management of maxillofacial uremic osteodystrophy: a case report. J Oral Maxillofac Surg, 65(9), 1825-9. (Read full article)

    Letter

    1. Spivak AM, Siliciano RF (2010). Using highly active antiretroviral therapy to decrease perioperative HIV-1 transmission risk. [Letter to the editor]. AIDS, 24(10), 1603-4; author reply 1604. (Read full article)

  • News & Podcasts

    News

    Podcasts

Schedule Online